Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.68 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.68 |
| ▸ | EGFR | P00533 | 2/20 | 0.68 |
| ▸ | SMC2 | O95347 | 1/20 | 0.68 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.68 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.68 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.68 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.68 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | NQO2 | P16083 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30746853 | 0.92 | MAP2K1 (0.81) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL1040194 | 0.92 | MAP2K1 (0.81) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL1037416 | 0.89 | MAP2K1 (0.84) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL4546010 | 0.84 | MAP2K1 (0.87) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL22567807 | 0.84 | MAP2K1 (0.80) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL4546015 | 0.83 | MAP2K1 (0.82) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL4546039 | 0.82 | MAP2K1 (0.80) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL19141419 | 0.82 | MAP2K1 (0.72) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL12957429 | 0.81 | MAP2K1 (0.72) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 | |
| SCHEMBL18752886 | 0.81 | MAP2K1 (0.65) | MAP2K1MAP2K2EGFRSMC2CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003805-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7973170-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110158971-A1 | COMPOSITIONS COMPRISING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-06-30 | — | — | US | disclosed |
| EP-2275102-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | Array Biopharma, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110158971-A1 | COMPOSITIONS COMPRISING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS AND METHODS OF USE THEREOF | NRAS, BRAF, CCNI | MAP2K1 257/4885MAP2K2 167/4885EGFR 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.